https://www.curasight.com/https://www.curasight.com/about-us/https://www.curasight.com/about-us/our-motivation/https://www.curasight.com/about-us/management-team/https://www.curasight.com/about-us/board-of-directors/https://www.curasight.com/about-us/history/https://www.curasight.com/upar-the-target/https://www.curasight.com/upar-the-target/upar-theranostics/https://www.curasight.com/upar-the-target/utrace/https://www.curasight.com/upar-the-target/utreat/https://www.curasight.com/upar-the-target/disease-areas/https://www.curasight.com/upar-the-target/publications/https://www.curasight.com/search/https://www.curasight.com/terms-of-use/https://www.curasight.com/pipeline/https://www.curasight.com/news/https://www.curasight.com/news/press-releases/https://www.curasight.com/news/press-releases/2026/curasight-to-hold-meetings-in-san-francisco-during-j-p-morgan-healthcare-conference-week/https://www.curasight.com/news/press-releases/2026/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating-first-in-class-radiopharmaceutical-utreat-in-high-grade-gliomas/https://www.curasight.com/news/press-releases/2026/major-shareholding-notification/https://www.curasight.com/news/press-releases/2026/curasight-to-present-at-td-cowens-46th-annual-health-care-conference-in-boston/https://www.curasight.com/news/press-releases/2026/year-end-report-q4-2025/https://www.curasight.com/news/press-releases/2026/annual-report-2025/https://www.curasight.com/news/press-releases/2026/curasight-reduces-convertible-debt-as-fenja-capital-converts-and-enters-into-a-block-trade/https://www.curasight.com/news/press-releases/2026/notice-of-annual-general-meeting-2026/https://www.curasight.com/news/press-releases/2026/resolutions-of-the-annual-general-meeting-2026-of-curasight-as/https://www.curasight.com/news/press-releases/2025/transaction-with-shares-in-curasight-as-made-by-managerial-employee/https://www.curasight.com/news/press-releases/2025/curasight-announces-broadening-and-extension-of-patent-protection-for-utrace/https://www.curasight.com/news/press-releases/2025/curasight-advances-phase-2-utrace-prostate-cancer-trial-with-all-european-clinical-sites-in-part-2-now-recruiting/https://www.curasight.com/news/press-releases/2025/curasight-to-present-at-dansk-aktionaerforening-investordagen/https://www.curasight.com/news/press-releases/2025/curasights-utreat-phase-1-trial-in-brain-cancer-now-open-for-patient-enrollment/https://www.curasight.com/news/press-releases/2025/interim-report-q3-2025/https://www.curasight.com/news/press-releases/2025/curasight-to-present-at-hc-andersen-capital-2025-11-28/https://www.curasight.com/news/press-releases/2025/curasight-as-announces-its-intention-to-carry-out-a-directed-issue-of-shares-and-enter-into-a-new-loan-facility/https://www.curasight.com/news/press-releases/2025/curasight-as-has-successfully-completed-a-directed-issue-of-shares-of-approximately-dkk-16-4-million-and-has-entered-into-a-new-loan-facility/https://www.curasight.com/news/press-releases/2025/notice-of-extraordinary-general-meeting/https://www.curasight.com/news/press-releases/2025/curasight-announces-successful-dosing-of-first-patient-in-phase-1-trial-with-utreat-in-brain-cancer/https://www.curasight.com/news/press-releases/2025/resolutions-of-the-extraordinary-general-meeting-december-2025/https://www.curasight.com/news/press-releases/2025/curasight-as-resolves-to-issue-a-convertible-loan-note/https://www.curasight.com/news/press-releases/2025/curasight-announces-an-updated-financial-calendar-2025/https://www.curasight.com/news/press-releases/2025/year-end-report-q4-2024/https://www.curasight.com/news/press-releases/2025/curasight-announces-new-date-of-the-annual-general-meeting-and-an-updated-financial-calendar-2025/https://www.curasight.com/news/press-releases/2025/curasight-as-resolves-on-its-intention-to-carry-out-a-rights-issue-of-shares-of-approximately-dkk-100-million/https://www.curasight.com/news/press-releases/2025/notice-of-extraordinary-general-meeting-of-curasight-as/https://www.curasight.com/news/press-releases/2025/resolutions-of-the-extraordinary-general-meeting-of-curasight-as-on-23-april-2025/https://www.curasight.com/news/press-releases/2025/curasight-as-announces-final-terms-of-rights-issue/https://www.curasight.com/news/press-releases/2025/interim-report-q1-2025/https://www.curasight.com/news/press-releases/2025/annual-report-for-the-fiscal-year-2024/https://www.curasight.com/news/press-releases/2025/curasight-as-publishes-disclosure-document-regarding-rights-issue/https://www.curasight.com/news/press-releases/2025/curasight-to-present-at-hc-andersen-capital/https://www.curasight.com/news/press-releases/2025/the-subscription-period-in-curasights-rights-issue-of-shares-begins-today/https://www.curasight.com/news/press-releases/2025/curasight-as-selects-cro-to-run-phase-1-trial-with-utreat-in-brain-cancer/https://www.curasight.com/news/press-releases/2025/last-day-of-the-subscription-period-in-curasights-rights-issue-of-shares/https://www.curasight.com/news/press-releases/2025/notice-of-annual-general-meeting-2025/https://www.curasight.com/news/press-releases/2025/subscription-of-new-shares-in-the-right-issue-2025-exercised-by-curasight-management/https://www.curasight.com/news/press-releases/2025/curasight-announces-outcome-in-rights-issue/https://www.curasight.com/news/press-releases/2025/resolutions-of-the-annual-general-meeting-2025-of-curasight-as/https://www.curasight.com/news/press-releases/2025/completed-registration-of-rights-issue/https://www.curasight.com/news/press-releases/2025/curasight-carries-out-a-directed-issue-of-shares-to-guarantors-in-connection-with-the-completed-rights-issue/https://www.curasight.com/news/press-releases/2025/the-exercise-period-commences-for-warrants-of-series-to3-on-4-june-2025/https://www.curasight.com/news/press-releases/2025/curasight-as-submits-clinical-trial-application-for-phase-1-trial-with-utreat-in-brain-cancer-patients/https://www.curasight.com/news/press-releases/2025/curasight-as-announces-outcome-of-t03-warrant-exercise/https://www.curasight.com/news/press-releases/2025/curasight-announces-acceptance-of-clinical-trial-application-cta-for-phase-1-trial-with-utreat-in-brain-cancer-patients/https://www.curasight.com/news/press-releases/2025/half-year-report-q2-2025/https://www.curasight.com/news/press-releases/2024/curasight-as-achieves-first-milestone-under-collaboration-with-curium-inc/https://www.curasight.com/news/press-releases/2024/year-end-report-october-december-2023/https://www.curasight.com/news/press-releases/2024/annual-report-for-the-fiscal-year-2023/https://www.curasight.com/news/press-releases/2024/notice-of-annual-general-meeting-2024/https://www.curasight.com/news/press-releases/2024/curasight-not-to-proceed-with-rights-issue-evaluating-alternative-financing-opportunities/https://www.curasight.com/news/press-releases/2024/resolutions-of-the-annual-general-meeting-2024-of-curasight-as/https://www.curasight.com/news/press-releases/2024/curasight-announces-change-in-the-board-of-directors/https://www.curasight.com/news/press-releases/2024/curasight-announces-approval-of-clinical-trial-application-cta-for-phase-2-trial-with-utrace-in-prostate-cancer-patients/https://www.curasight.com/news/press-releases/2024/interim-report-q1-2024/https://www.curasight.com/news/press-releases/2024/curasight-announces-enrollment-of-first-patient-in-phase-2-trial-with-utrace-in-prostate-cancer/https://www.curasight.com/news/press-releases/2024/curasight-as-resolves-on-directed-issues-and-a-loan-facility/https://www.curasight.com/news/press-releases/2024/notice-of-extraordinary-general-meeting/https://www.curasight.com/news/press-releases/2024/curasight-to-present-at-hc-andersen-capital/https://www.curasight.com/news/press-releases/2024/directed-issues-registered-at-the-danish-business-authority/https://www.curasight.com/news/press-releases/2024/resolutions-of-the-extraordinary-general-meeting-of-curasight-as-on-2-july-2024/https://www.curasight.com/news/press-releases/2024/curasight-issues-warrants-as-part-of-long-term-incentive-program/https://www.curasight.com/news/press-releases/2024/interim-report-q2-2024/https://www.curasight.com/news/press-releases/2024/the-board-of-directors-resolves-on-a-directed-issue-of-units-and-preferential-rights-issue-of-units/https://www.curasight.com/news/press-releases/2024/commencement-of-subscription-period-in-curasights-preferential-rights-issue/https://www.curasight.com/news/press-releases/2024/curasight-as-rights-issue-heavily-oversubscribed/https://www.curasight.com/news/press-releases/2024/curasight-as-announces-last-day-of-trading-in-btu-and-first-day-of-trading-in-warrant-series-to2-and-to3/https://www.curasight.com/news/press-releases/2024/clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients-published-data-supports-development-of-utreat-for-brain-cancer/https://www.curasight.com/news/press-releases/2024/curasight-to-present-at-dansk-aktionaerforening-investordagen/https://www.curasight.com/news/press-releases/2024/curasight-announces-brain-cancer-as-first-indication-for-utreat-first-patient-to-be-dosed-q2-2025/https://www.curasight.com/news/press-releases/2024/curasight-announces-international-patent-application-for-utreat-to-broaden-ip-protection/https://www.curasight.com/news/press-releases/2024/curasight-to-present-at-hc-andersen-capital-biostock-life-science-summit-2024-and-okonomisk-ugebrev-investor-conference/https://www.curasight.com/news/press-releases/2024/the-exercise-price-for-warrants-of-series-to2-has-been-set-to-dkk-11-50-per-new-share/https://www.curasight.com/news/press-releases/2024/interim-report-q3-2024/https://www.curasight.com/news/press-releases/2024/the-exercise-period-for-warrants-of-series-to2-commences-today/https://www.curasight.com/news/press-releases/2024/curasight-and-curium-sign-global-radioisotope-supply-agreement-for-utreat/https://www.curasight.com/news/press-releases/2024/the-last-day-of-trading-in-warrants-of-series-to2-is-on-the-3rd-of-december-2024/https://www.curasight.com/news/press-releases/2024/seb-maintain-valuation-range-midpoint-at-dkk-54-per-share/https://www.curasight.com/news/press-releases/2024/curasight-as-announces-outcome-of-warrant-exercise/https://www.curasight.com/news/press-releases/2024/participation-in-warrant-exercise-by-curasight-management/https://www.curasight.com/news/press-releases/2023/curasight-to-present-at-redeye-fight-cancer-seminar/https://www.curasight.com/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital/https://www.curasight.com/news/press-releases/2023/year-end-report-october---december-2022/https://www.curasight.com/news/press-releases/2023/annual-report-for-the-fiscal-year-2022/https://www.curasight.com/news/press-releases/2023/notice-of-annual-general-meeting-2023/https://www.curasight.com/news/press-releases/2023/resolutions-of-the-annual-general-meeting-of-curasight-as/https://www.curasight.com/news/press-releases/2023/curasight-and-curium-announce-global-partnership-for-utrace-in-prostate-cancer/https://www.curasight.com/news/press-releases/2023/interim-report-q1-2023/https://www.curasight.com/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital-and-okonomisk-ugebrev/https://www.curasight.com/news/press-releases/2023/curasight-as-reports-positive-preclinical-results-with-utreat-in-aggressive-brain-cancer-glioblastoma/https://www.curasight.com/news/press-releases/2023/positive-results-in-upar-petmr-phase-ii-study-in-brain-cancer/https://www.curasight.com/news/press-releases/2023/interim-report-january--june-2023/https://www.curasight.com/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital-and-at-hc-andersen-life-science-seminar/https://www.curasight.com/news/press-releases/2023/positive-results-from-the-phase-ii-study-of-utrace-in-brain-cancer-presented-at-the-world-molecular-imaging-congress-wmic-2023-in-prague/https://www.curasight.com/news/press-releases/2023/curasight-as-reports-positive-preclinical-results-with-utreat-in-lung-cancer-nsclc/https://www.curasight.com/news/press-releases/2023/interim-report-january--september-2023/https://www.curasight.com/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital-and-stokkio/https://www.curasight.com/news/press-releases/2023/curasight-as-appoints-cro-to-run-phase-2-study-with-utrace-in-prostate-cancer/https://www.curasight.com/news/press-releases/2023/curasight-as-submits-clinical-trial-application-cta-for-phase-2-trial-with-utrace-in-prostate-cancer-patients/https://www.curasight.com/news/press-releases/2022/curasight-presents-at-the-seb-nordic-healthcare-seminar-2022-and-at-kapital-partner/https://www.curasight.com/news/press-releases/2022/phase-ii-study-of-upar-pet-in-neuroendocrine-tumor-patients-demonstrates-strong-prognostic-value-and-supports-potential-future-use-of-upar-targeted-radionuclide-therapy/https://www.curasight.com/news/press-releases/2022/curasight-strengthens-its-strategic-position-with-the-acquisition-of-trt-innovations-aps/https://www.curasight.com/news/press-releases/2022/curasight-expands-its-strategy-and-strengthen-its-position-as-a-theranostic-company/https://www.curasight.com/news/press-releases/2022/year-end-report-october---december-2021/https://www.curasight.com/news/press-releases/2022/annual-report-for-the-fiscal-year-2021/https://www.curasight.com/news/press-releases/2022/curasight-announces-new-date-of-the-annual-general-meeting-and-an-updated-financial-calendar-2022/https://www.curasight.com/news/press-releases/2022/notice-of-annual-general-meeting-2022/https://www.curasight.com/news/press-releases/2022/additional-us-patent-application-relating-to-utrace-is-accepted-for-grant/https://www.curasight.com/news/press-releases/2022/resolutions-of-the-annual-general-meeting-of-curasight-as/https://www.curasight.com/news/press-releases/2022/curasight-to-present-at-kapital-partners-life-science-seminar/https://www.curasight.com/news/press-releases/2022/interim-report-january---march-2022/https://www.curasight.com/news/press-releases/2022/curasight-issues-warrants-for-launch-of-long-term-incentive-program/https://www.curasight.com/news/press-releases/2022/transaction-with-shares-in-curasight-as-made-by-managerial-employee/https://www.curasight.com/news/press-releases/2022/recruitment-completed-in-upar-pet-study-in-brain-cancer/https://www.curasight.com/news/press-releases/2022/interim-report-january--june-2022/https://www.curasight.com/news/press-releases/2022/curasight-to-present-at-hc-andersen-capital/https://www.curasight.com/news/press-releases/2022/transaction-with-shares-in-curasight-as-made-by-managerial-employee-2022-09-04/https://www.curasight.com/news/press-releases/2022/curasight-initiates-pre-clinical-studies-with-utreat-therapy-in-head-and-neck-cancer-hnscc-and-neuroendocrine-tumors-net/https://www.curasight.com/news/press-releases/2022/curasight-to-present-at-seb-healthcare-seminar-2022/https://www.curasight.com/news/press-releases/2022/curasight-to-present-at-hc-andersen-capital-2022-11-23/https://www.curasight.com/news/press-releases/2022/interim-report-january--september-2022/https://www.curasight.com/news/press-releases/2021/curasight-as-strengthens-its-institutional-investor-base/https://www.curasight.com/news/press-releases/2021/the-exercise-period-for-warrants-of-series-to-1-in-curasight-as-begins-today/https://www.curasight.com/news/press-releases/2021/transactions-with-warrants-of-series-to-1-in-curasight-as-made-by-managerial-employees-and-their-closely-associated-persons/https://www.curasight.com/news/press-releases/2021/curasight-warrant-to-1--last-day-of-trading-is-tuesday-5-october-2021/https://www.curasight.com/news/press-releases/2021/curasight-as-receives-approximately-dkk-476-million-through-exercise-of-warrants-of-series-to-1/https://www.curasight.com/news/press-releases/2021/curasight-as-warrant-exercise-registered-at-erhvervsstyrelsen/https://www.curasight.com/news/press-releases/2021/curasight-as-presents-at-biostock-life-science-summit-20-october-2021/https://www.curasight.com/news/press-releases/2021/curasight-as-presents-at-okonomisk-ugebrev-life-science-investor-conference-in-copenhagen-20-october-2021/https://www.curasight.com/news/press-releases/2021/curasight-presents-at-hc-andersen-capital-2021-11-23/https://www.curasight.com/news/press-releases/2021/interim-report-january--september-2021/https://www.curasight.com/news/press-releases/2021/curasight-as-presents-at-sedermeradagen-in-copenhagen-7-december-2021/https://www.curasight.com/news/press-releases/2021/curasight-as-presents-at-hc-andersen-capital--nordea-markets-virtual-growth-days-seminar---9-december-2021/https://www.curasight.com/news/press-releases/2021/phase-ii-study-demonstrates-prognostic-value-of-upar-pet-in-head-and-neck-cancer-patients/https://www.curasight.com/news/press-releases/2021/curasight-presents-at-hc-andersen-capital-2021-12-13/https://www.curasight.com/news/press-releases/2021/transaction-with-shares-in-curasight-as-made-by-managerial-employee/https://www.curasight.com/news/press-releases/2021/hanne-damgaard-jensen-joins-curasight-as-as-chief-development-officer-cdo/https://www.curasight.com/news/press-releases/2021/curasight-attends-the-jp-morgan-healthcare-conference-and-presents-at-hc-andersen-capital/https://www.curasight.com/news/press-releases/2021/interim-report-january--june-2021/https://www.curasight.com/news/press-releases/2021/curasight-presents-at-hc-andersen-capital/https://www.curasight.com/news/press-releases/2021/us-patent-application-14399820-relating-to-utreat-is-accepted-for-grant/https://www.curasight.com/news/press-releases/2021/year-end-report-october--december-2020/https://www.curasight.com/news/press-releases/2021/annual-report-for-the-fiscal-year-2020/https://www.curasight.com/news/press-releases/2021/article-from-phase-ii-study-in-prostate-cancer-now-published-in-the-march-issue-of-journal-of-nuclear-medicine-and-highlighted-as-best-clinical-investigation-article/https://www.curasight.com/news/press-releases/2021/curasight-as-presents-at-okonomisk-ugebrev-life-science-investor-conference/https://www.curasight.com/news/press-releases/2021/notice-of-annual-general-meeting/https://www.curasight.com/news/press-releases/2021/curasights-presentation-at-okonomisk-ugebrev-life-science-investor-conference-is-now-available/https://www.curasight.com/news/press-releases/2021/minutes-from-the-annual-general-meeting-in-curasight-as/https://www.curasight.com/news/press-releases/2021/cad-patent-application-2905172-relating-to-utreat-is-accepted-for-grant/https://www.curasight.com/news/press-releases/2021/curasight-as-presents-at-nordnet-live---spotlight-small-cap-investor-conference-15-april-2021/https://www.curasight.com/news/press-releases/2021/curasight-announces-appointment-of-dr-kirsten-drejer-as-new-board-member/https://www.curasight.com/news/press-releases/2021/curasight-is-awarded-two-prizes-in-best-ipo-2020-by-the-independent-ipo-guide/https://www.curasight.com/news/press-releases/2021/notice-of-extraordinary-general-meeting/https://www.curasight.com/news/press-releases/2021/interim-report-january--march-2021/https://www.curasight.com/news/press-releases/2021/interim-report-january--march-2021--correction/https://www.curasight.com/news/press-releases/2021/curasight-presents-at-erik-penser-bank--temadag-medicinsk-bildteknik--diagnostik/https://www.curasight.com/news/press-releases/2021/curasight-presents-at-bio-stock-life-science-spring-summit/https://www.curasight.com/news/press-releases/2021/minutes-from-the-extraordinary-general-meeting-in-curasight-as/https://www.curasight.com/news/press-releases/2021/seb-initiates-commissioned-research-on-curasight-as/https://www.curasight.com/news/press-releases/2021/positive-data-of-utreat-in-glioblastoma-provides-green-light-to-proceed-with-next-steps/https://www.curasight.com/news/press-releases/2020/the-subscription-period-in-curasights-issue-of-units-starts-today/https://www.curasight.com/news/press-releases/2020/curasight-as-receives-approval-for-listing-and-publishes-prospectus/https://www.curasight.com/news/press-releases/2020/webcast-with-curasight/https://www.curasight.com/news/press-releases/2020/significantly-oversubscribed-ipo-of-units-in-curasight/https://www.curasight.com/news/press-releases/2020/first-day-of-trading-in-curasights-shares-and-warrants-at-spotlight-stock-market/https://www.curasight.com/news/press-releases/2020/prolongation-and-expansion-of-agreement-with-trt-innovations-aps/https://www.curasight.com/news/press-releases/2020/canadian-patent-application-relating-to-utrace-is-ready-for-allowance-in-canada/https://www.curasight.com/news/press-releases/2020/curasight-initiates-pre-clinical-study-on-therapy-utreat-in-brain-cancer-and-signs-cro-agreement/https://www.curasight.com/news/press-releases/2020/interim-report-january--september-2020/https://www.curasight.com/news/press-releases/2020/financial-calendar-2021/https://www.curasight.com/news/press-releases/2020/japanese-patent-application-2019-005811-is-accepted-for-grant/https://www.curasight.com/news/press-releases/2020/results-from-phase-ii-study-in-prostate-cancer-to-be-published-in-the-journal-of-nuclear-medicine/https://www.curasight.com/news/presentations/https://www.curasight.com/news/news/https://www.curasight.com/news/news/2021/august-24-2021/https://www.curasight.com/news/news/2019/october-30-2019/https://www.curasight.com/news/news/2018/may-22-2018/https://www.curasight.com/news/news/2018/march-1-2018/https://www.curasight.com/news/news/2017/march-1-2017/https://www.curasight.com/news/news/2017/november-21-2017/https://www.curasight.com/news/news/2017/july-1-2017/https://www.curasight.com/news/news/2017/april-1-2017/https://www.curasight.com/news/news/2016/october-30-2016/https://www.curasight.com/news/news/2016/september-15-2016/https://www.curasight.com/news/curasight-in-the-media/https://www.curasight.com/news/subscribe/https://www.curasight.com/news/frequently-asked-questions/https://www.curasight.com/investor/https://www.curasight.com/investor/curasight-as-an-investment/https://www.curasight.com/investor/reports/https://www.curasight.com/investor/reports/year-end-report-october-december-2023/https://www.curasight.com/investor/reports/annual-report-for-the-fiscal-year-2023/https://www.curasight.com/investor/reports/interim-report-q1-2024/https://www.curasight.com/investor/reports/interim-report-q2-2024/https://www.curasight.com/investor/reports/interim-report-q3-2024/https://www.curasight.com/investor/reports/year-end-report-q4-2024/https://www.curasight.com/investor/reports/interim-report-q1-2025/https://www.curasight.com/investor/reports/annual-report-for-the-fiscal-year-2024/https://www.curasight.com/investor/reports/half-year-report-q2-2025/https://www.curasight.com/investor/reports/interim-report-q3-2025/https://www.curasight.com/investor/reports/year-end-report-q4-2025/https://www.curasight.com/investor/reports/annual-report-2025/https://www.curasight.com/investor/the-share/https://www.curasight.com/investor/general-meetings/https://www.curasight.com/investor/calendar/https://www.curasight.com/investor/calendar/2022/seb-annual-healthcare-seminar/https://www.curasight.com/investor/calendar/2022/interim-report-q3-2022-presentation-at-hc-andersen-capital/https://www.curasight.com/investor/calendar/2022/hc-andersen-capital-virtual-nordic-growth-days/https://www.curasight.com/investor/calendar/2021/presentation-at-biostock-life-science-summit/https://www.curasight.com/investor/calendar/2021/presentation-at-okonomisk-ugebrev-life-science-investor-conference-in-copenhagen/https://www.curasight.com/investor/calendar/2021/q3-presentation-at-hc-andersen-capital/https://www.curasight.com/investor/events/https://www.curasight.com/investor/corporate-governance/https://www.curasight.com/investor/analyst-coverage/https://www.curasight.com/investor/archive-financing/https://www.curasight.com/investor/archive-financing/rights-issue-2024/https://www.curasight.com/investor/archive-financing/warrants-2021/https://www.curasight.com/investor/archive-financing/ipo-2020/https://www.curasight.com/contact/